Zevra Therapeutics, Inc. (1GDA.F)

4.6200 -0.1000 (-2.12%) As of 08:04AM CEST. Market open.

Zevra Therapeutics, Inc.

1180 Celebration Boulevard
Suite 103
Celebration, FL 34747
United States
321 939 3416
https://zevra.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 65

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Neil F. McFarlane	President, CEO & Director	468.79k	N/A	1973
Ms. Christal M. M. Mickle M.A.	Co-Founder & Chief Development Officer	579.14k	N/A	1979
Mr. R. LaDuane Clifton CPA	CFO, Secretary & Treasurer	612.71k	N/A	1972
Mr. Joshua M. Schafer M.B.A.	Chief Commercial Officer & Executive VP of Business Development	712.87k	N/A	1972
Dr. Sven Guenther Ph.D.	Chief Scientific Officer	462.73k	N/A	1972
Ms. Nichol L. Ochsner	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Christopher M. Lauderback Ph.D.	Senior Vice President of Manufacturing	N/A	N/A	1975
Dr. Rene A. Braeckman Ph.D.	Senior Vice President of Clinical Development	N/A	N/A	N/A
Dr. Daniel Gallo Ph.D.	Senior Vice President of Medical Affairs & Advocacy	N/A	N/A	N/A
Dr. Adrian Quartel FFPM, M.D.	Chief Medical Officer	N/A	N/A	1961

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Corporate governance

Zevra Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.